The US Court of Appeals for the Federal Circuit reverses a judgment that upheld “skinny labels” and allowed a generic to launch on uses not covered by a patent (GlaxoSmithKline / Teva)

On October 2, 2020, the U.S. Court of Appeals for the Federal Circuit vacated a district court’s judgment in favor of defendant Teva in a case involving “skinny labels.” GlaxoSmithKline LLC v. Teva Pharm. USA, Inc., 976 F.3d 1347 (Fed. Cir. 2020). When a drug can be used to treat multiple conditions, a generic can “carve out” the patented indications from its label. 21 U.S.C. § 355(j)(2)(A)(viii) (“section viii”). The resulting “skinny label” allows the generic to launch its product for uses not covered by the patent. GlaxoSmithKline LLC and SmithKline Beecham (Cork) Ltd. (together, “GSK”) sued Teva Pharmaceuticals USA, Inc. (Teva) for patent infringement. After a trial in the U.S. District Court for the District of Delaware, the jury found the patent valid and infringed, and assessed damages.

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

Michael A. Carrier, The US Court of Appeals for the Federal Circuit reverses a judgment that upheld “skinny labels” and allowed a generic to launch on uses not covered by a patent (GlaxoSmithKline / Teva), 2 octobre 2020, e-Competitions October 2020, Art. N° 98366

Visites 58

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues